Klein Ronald, Knudtson Michael D, Klein Barbara E K
Department of Ophthalmology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53726, USA.
Am J Ophthalmol. 2007 Jul;144(1):1-6. doi: 10.1016/j.ajo.2007.02.047. Epub 2007 May 2.
To examine the association of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) with the five-year incidence of age-related macular degeneration (AMD).
Population-based cohort study.
settings: Beaver Dam, Wisconsin. study population: Participants included persons 53 to 96 years of age at examination in 1998 to 2000 (n = 2,962), of whom 2,204 participated in a follow-up five years later. observation procedures: Standardized procedures were used for physical examinations, blood collection, and questionnaire administration. AMD was determined by grading images of the posterior pole using a standard protocol. Standard univariate and multivariate analyses were performed. main outcome measures: Incident early and late AMD and progressed AMD.
There were 1,347 and 1,638 persons not using statins and 339 and 429 using statins at the 1998 to 2000 examination at risk of early and late AMD, respectively. The unadjusted five-year incidence of early and late AMD, respectively, was 5.9% and 1.8% in those not using statins and 6.8% and 2.3% in those using statins. While controlling for age, gender, smoking status, and multivitamin use, a history of statin use was not associated with the five-year incidence of early AMD (odds ratio [OR] 1.16, 95% confidence interval [CI] 0.71 to 1.91, P = .55), progression of AMD (OR 1.16, 95% CI 0.75 to 1.78, P = .51) or incidence of late AMD (OR 1.27, 95% CI 0.60 to 2.69. P = .53).
These findings do not show an association between statin use and the incidence or progression of AMD over a five-year period.
研究羟甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂（他汀类药物）与年龄相关性黄斑变性（AMD）五年发病率之间的关联。
基于人群的队列研究。
地点：威斯康星州比弗迪尔。研究人群：参与者包括1998年至2000年接受检查时年龄在53至96岁之间的人（n = 2962），其中2204人在五年后参与了随访。观察程序：采用标准化程序进行体格检查、血液采集和问卷调查。通过使用标准方案对后极部图像进行分级来确定AMD。进行了标准的单变量和多变量分析。主要观察指标：早期和晚期AMD的发病情况以及进展性AMD。
在1998年至2000年的检查中，分别有1347人和1638人未使用他汀类药物，有339人和429人使用他汀类药物，他们有早期和晚期AMD的风险。未使用他汀类药物者早期和晚期AMD的未调整五年发病率分别为5.9%和1.8%，使用他汀类药物者分别为6.8%和2.3%。在控制年龄、性别、吸烟状况和多种维生素使用情况后，他汀类药物使用史与早期AMD的五年发病率（优势比[OR] 1.16，95%置信区间[CI] 0.71至1.91，P = 0.55）、AMD的进展（OR 1.16，95% CI 0.75至1.78，P = 0.51）或晚期AMD的发病率（OR 1.27，95% CI 0.60至2.69，P = 0.53）均无关联。
这些发现未显示他汀类药物使用与五年内AMD的发病率或进展之间存在关联。
